StemCell Therapy

CARLSBAD, Calif. (May 05, 2011) - At the annual shareholders meeting of International Stem Cell Corporation (OTCBB:ISCO) on May 3, 2011, Kenneth Aldrich, Chairman and co-founder of ISCO conducted a presentation to shareholders that included the following remarks:

Good morning to all our shareholders and friends of ISCO. Let me make just a few comments about where we are and the progress we have made over the last year. All of the developments and news I will discuss were announced in the past 12 months, but with the passage of time it is easy to lose track of how much progress ISCO has actually made. I won’t mention everything—we don’t have that much time, but some highlights will, I hope, help put these recent achievements into perspective.

A little less than a year ago, in June 2010, our first parthenogenetic patent application was formally approved by the US Patent Office. More applications are pending, but this approval established ISCO as the lawful owner of the rights to produce human stem cell lines through parthenogenesis. That is a platform on which we expect to build for a long time.

Also in June we eliminated all of our outstanding corporate debt and we remain debt free.

In July we announced the signing of a distribution contract with Sristi Biosciences, a major seller of research products in India, which continues the international commercial expansion of our Lifeline Cell Technology^® brand.

In October we announced the first steps toward the formation of a major funded collaboration in India with Insight Bioventures India Private Limited (IBVI) to develop treatments for corneal damage and retinal disease. Planning for that work is ongoing and the Executive Director of Insight Bioventures has flown in from India to meet with us today, so we remain very optimistic about this project.

In November, we presented the results of scientific studies demonstrating a new and better method for differentiating our parthenogenetic cells into liver cells, a critical step toward using them to treat liver disease.

In November and December we launched the first test marketing runs of our new skin crème products, first to our own shareholders and friends, then to a select mailing list developed by our marketing partner, John Mauldin. Those resulted in sales of over 7,000 bottles of our new products.

In December we established $25 million financing commitment that provides access to capital on an as-needed basis over a three year period, but never requires the sale of stock unless we think it will benefit the company and its shareholders. This agreement provides us a high degree of flexibility in meeting our financial needs.

In January 2011 we announced publication of peer-reviewed studies further validating the functional equivalency of our parthenogenetic stem cells with embryonic stem cells. These studies confirm our ability to benefit from much of the millions of dollars of research on embryonic stem cells over the last decade. In short, we have a running start in the search for cures.

Throughout the year we have made steady progress in development of liver cells and liver precursor cells, culminating in an announcement in April of this year that we had successfully completed the first in a series of pre-clinical tests of parthenogenetically derived liver cells.

Last, but by no means least, we have received the necessary approvals for creating new Parthenogenetic Stem Cell Lines in the United States. These will be clinical grade lines suitable for human trials, and are the first major step in this country to begin building a “Bank” of stem cells enabling the matching of immune systems of millions of people worldwide, with the potential to eliminate or reduce the harmful effects of immune suppressing drugs that would normally have to be used with stem cell transplant procedures.

All of these news stories and more are available on our website along with presentations we have made recently to investors in the US and Europe. On behalf of the Board of Directors and everyone at ISCO, I thank you for your support.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contact:

International Stem Cell Corporation

Kenneth C Aldrich, Chairman

760-940-6383

kaldrich@intlstemcell.com

# # #

Data from successful animal study using liver cells derived from human parthenogenetic stem cells to be presented at two upcoming scientific conferences

Company also announces collaboration with Cedars-Sinai Medical Center for liver disease research, and completion of research on cytochrome P450 activity

International Stem Cell Corporation (OTCBB:ISCO) (ISCO) announces successful completion of the first series of preclinical testing of hepatocytes derived in the lab from human parthenogenetic stem cells (hpSC). In the transplantation mouse model, inoculated cells were capable of engrafting and surviving in specific niches within the liver, and were further developing into cells with essential hepatocyte-like features. Moreover, the transplanted cells could be identified in recipient tissue for a prolonged period of time.

The findings of these studies will be presented at the annual meeting of American Society of Gene & Cell Therapy, May 18-21 in Seattle, and at the International Society for Stem Cell Research annual conference, June 15-18 in Toronto.

"These results mark the achievement of a key milestone in our preclinical research," said Andrey Semechkin, Ph.D., ISCO's Chief Executive Officer. "Specifically, we have perfected the technique to transplant hepatocytes, an extremely fragile cell type, into the liver of animals, which is an easily injured organ. This preclinical research helps us develop our collaborations with clinics."

Nikolay Turovets, Ph.D., ISCO's Director of Research and Therapeutic Development commented "The next phase of research is to conduct experiments to demonstrate the ability of the transplanted cells to perform the vital functions of normal hepatocytes and, accordingly, their ability to modify disease by restoring the missing function of a patient's diseased liver."

The Company also announces the signing of a joint collaboration agreement with Cedars-Sinai Medical Center in Los Angeles to conduct research to develop therapies for liver diseases, in particular urea cycle disorders. Jeffrey Fair, MD., a liver transplant surgeon and Director of Translational Research for the Cedars-Sinai Comprehensive Transplant Center and Department of Surgery, will lead the Cedars-Sinai research team.

Dr. Fair said, "Urea cycle disorders are genetic deficiencies of liver function, which mostly affect newborns and oftentimes cause catastrophic neurological injury. It has been shown that transplantation of donor hepatocytes can save patient lives. Therefore, derivation of hepatocytes from hpSCs that can be immune-matched to the patient is a very pressing goal."

The Company also announces the completion of research focused on the investigation of cytochrome P450 activity and corresponding genes in hepatocytes derived from hpSC. According to the results, the differentiation technology developed by ISCO allows the creation of hepatocytes in the fetal stage of development. This research may contribute to the design of a product for future drug testing and discovery.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Nikolay Turovets, Ph.D.
Director, Research and Therapeutic Development
nturovets@intlstemcell.com

Data from successful animal study using liver cells derived from human parthenogenetic stem cells to be presented at two upcoming scientific conferences

Company also announces collaboration with Cedars-Sinai Medical Center for liver disease research, and completion of research on cytochrome P450 activity

International Stem Cell Corporation (OTCBB:ISCO) (ISCO) announces successful completion of the first series of preclinical testing of hepatocytes derived in the lab from human parthenogenetic stem cells (hpSC). In the transplantation mouse model, inoculated cells were capable of engrafting and surviving in specific niches within the liver, and were further developing into cells with essential hepatocyte-like features. Moreover, the transplanted cells could be identified in recipient tissue for a prolonged period of time.

The findings of these studies will be presented at the annual meeting of American Society of Gene & Cell Therapy, May 18-21 in Seattle, and at the International Society for Stem Cell Research annual conference, June 15-18 in Toronto.

"These results mark the achievement of a key milestone in our preclinical research," said Andrey Semechkin, Ph.D., ISCO's Chief Executive Officer. "Specifically, we have perfected the technique to transplant hepatocytes, an extremely fragile cell type, into the liver of animals, which is an easily injured organ. This preclinical research helps us develop our collaborations with clinics."

Nikolay Turovets, Ph.D., ISCO's Director of Research and Therapeutic Development commented "The next phase of research is to conduct experiments to demonstrate the ability of the transplanted cells to perform the vital functions of normal hepatocytes and, accordingly, their ability to modify disease by restoring the missing function of a patient's diseased liver."

The Company also announces the signing of a joint collaboration agreement with Cedars-Sinai Medical Center in Los Angeles to conduct research to develop therapies for liver diseases, in particular urea cycle disorders. Jeffrey Fair, MD., a liver transplant surgeon and Director of Translational Research for the Cedars-Sinai Comprehensive Transplant Center and Department of Surgery, will lead the Cedars-Sinai research team.

Dr. Fair said, "Urea cycle disorders are genetic deficiencies of liver function, which mostly affect newborns and oftentimes cause catastrophic neurological injury. It has been shown that transplantation of donor hepatocytes can save patient lives. Therefore, derivation of hepatocytes from hpSCs that can be immune-matched to the patient is a very pressing goal."

The Company also announces the completion of research focused on the investigation of cytochrome P450 activity and corresponding genes in hepatocytes derived from hpSC. According to the results, the differentiation technology developed by ISCO allows the creation of hepatocytes in the fetal stage of development. This research may contribute to the design of a product for future drug testing and discovery.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Nikolay Turovets, Ph.D.
Director, Research and Therapeutic Development
nturovets@intlstemcell.com

International Stem Cell Corporation (OTCBB:ISCO) http://www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic and research products, announced today the selection of the Richards Partners as agency of record for its wholly owned subsidiary Lifeline Skin Care, Inc. ("Lifeline"). Lifeline offers luxury anti-aging skin care products based on its proprietary stem cell technology. Based in Dallas, the Richards Partners is the nation's largest independent branding agency.

Lifeline's skin care products were developed by a team of ISCO research scientists in collaboration with world-renowned cosmetic experts, and offer a comprehensive approach to skin care using patent pending moisture serums for day and night use. Made with human parthenogenetic stem cell extracts, the serums deliver anti-aging benefits, resulting in healthier and younger-looking skin. These products were launched in November 2010 and are available for purchase through the http://www.lifelineskincare.com website and selected luxury spas across the United States.

Adding Richards Partners to the Lifeline Skin Care^TM team is part of Lifeline's plan to build on its initial successful product launch last year, and the Web based sales that have followed, by initiating a series of new marketing campaigns to further develop the Lifeline Skin Care^TMbrand identity. These new marketing initiatives include traditional print and news media campaigns, as well as a new digital strategy focused on Internet and social media. "We are looking forward to working closely with the Richards Partners and leveraging their expertise in these areas to enhance the profile of Lifeline Skin Care^TM and its revolutionary new skin care products," says Lifeline CEO Ruslan Semechkin, PhD. "Building a globally recognizable brand is a long-term process and this is an important step towards creating Lifeline's name. We believe this is a good time to begin these campaigns and continue our sales momentum resulting from our successful initial launch," Dr. Semechkin continued.

As previously announced the Mauldin Group, Lifeline's marketing partner, will be managing the day to day relationship with the Richards Partners and planning additional direct marketing initiatives similar to the successful initial launch in 2010. Tiffani Mauldin-Frederick, marketing partner of Lifeline Skin Care^TM, says, "We're excited about working together with Richards Partners. We believe the collaboration will provide additional momentum and increase brand recognition for Lifeline Skin Care^TM and help educate the public about the revolutionary science behind these products."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care, anti-aging

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
ras@intlstemcell.com

International Stem Cell Corporation (OTCBB:ISCO) http://www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic and research products, announced today the selection of the Richards Partners as agency of record for its wholly owned subsidiary Lifeline Skin Care, Inc. ("Lifeline"). Lifeline offers luxury anti-aging skin care products based on its proprietary stem cell technology. Based in Dallas, the Richards Partners is the nation's largest independent branding agency.

Lifeline's skin care products were developed by a team of ISCO research scientists in collaboration with world-renowned cosmetic experts, and offer a comprehensive approach to skin care using patent pending moisture serums for day and night use. Made with human parthenogenetic stem cell extracts, the serums deliver anti-aging benefits, resulting in healthier and younger-looking skin. These products were launched in November 2010 and are available for purchase through the http://www.lifelineskincare.com website and selected luxury spas across the United States.

Adding Richards Partners to the Lifeline Skin Care^TM team is part of Lifeline's plan to build on its initial successful product launch last year, and the Web based sales that have followed, by initiating a series of new marketing campaigns to further develop the Lifeline Skin Care^TMbrand identity. These new marketing initiatives include traditional print and news media campaigns, as well as a new digital strategy focused on Internet and social media. "We are looking forward to working closely with the Richards Partners and leveraging their expertise in these areas to enhance the profile of Lifeline Skin Care^TM and its revolutionary new skin care products," says Lifeline CEO Ruslan Semechkin, PhD. "Building a globally recognizable brand is a long-term process and this is an important step towards creating Lifeline's name. We believe this is a good time to begin these campaigns and continue our sales momentum resulting from our successful initial launch," Dr. Semechkin continued.

As previously announced the Mauldin Group, Lifeline's marketing partner, will be managing the day to day relationship with the Richards Partners and planning additional direct marketing initiatives similar to the successful initial launch in 2010. Tiffani Mauldin-Frederick, marketing partner of Lifeline Skin Care^TM, says, "We're excited about working together with Richards Partners. We believe the collaboration will provide additional momentum and increase brand recognition for Lifeline Skin Care^TM and help educate the public about the revolutionary science behind these products."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care, anti-aging

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
ras@intlstemcell.com

http://www.cellmedicine.com

See the original post:
Stem Cell Therapy for Type II Diabetes

SIRA: Could Stem Cell Therapy Renew Your Body Cells? without comments. Join Evan Snyder, MD, Ph.D., from the Burnham Institute for Medical Research, for a look at the possible ...

The rest is here:
SIRA: Could Stem Cell Therapy Renew Your Body Cells? – Affordable ...

Stem cell therapy done at neurogen brain and spine institute pvt ltd. Tell: +91 9920 200 400 , 022 25281610 , 022 25283706

Read the original post:
Stem Cell Therapy for Cerebral Palsy

Stem Cell Therapy for your pet. For a FREE pet evaluation.

View original post here:
Is Stem Cell Therapy right for your pet

A year ago, 9-year-old Kenneth Kelley couldn't read.

Read more:
Stem Cell Treatment Doing Wonders For Autistic Boy

Stem cell therapy patient Trish Stressman discusses her recovery from spinal cord injury after undergoing stem cell treatments at the Stem Cell Institute in Panama City, Panama. Ms

Link:
Stem Cells for Spinal Cord Injury: Community Outreach San Diego 2011 - Trish Stressman

Two dogs in Polk County are getting stem cell therapy. The treatment is designed to help older dogs that have problems walking.

Read the original:
Dogs now getting stem cell therapy

see http://www.cellmedicine.com

See more here:
Stem Cell Therapy for Autism

http://www.cellmedicine.com stem cell therapy. Here we are discussing a publication showing bone marrow mesenchymal stem cells reduce kidney damage. Mesenchymal stem cells may have promise for treating diabetic renal failure.

See original here:
Stem Cell Therapy for Kidney Failure

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today the achievement of a major milestone in its efforts to establish a bank of immune-matched parthenogenetic stem cells in the United States by receiving the statutory approvals required to move forward with the next phase of its stem cell banking program.

An independent Stem Cell Research Oversight (SCRO) committee approved ISCO's program to obtain human oocytes (eggs) in California. The independent SCRO committee is responsible for reviewing the scientific rationale, ethics and compliance with State and Federal regulations and guidelines for studies involving human stem cells. This approval in combination with the earlier reported Institutional Review Board (IRB) clearance with regard to medical safety opens the way for ISCO's stem cell banking program to begin registering clinical investigators. ISCO's study is designed to produce new clinical-grade human parthenogenetic stem cell lines that can be immune matched to millions of individuals for use in the emerging field of regenerative medicine.

ISCO's breakthrough discoveries have resulted in unique stem cells carrying distinct advantages over other human pluripotent stem cells. ISCO uses unfertilized oocytes to create human "parthenogenetic" stem cells (hpSCs). Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals.

Currently ISCO has a collection of ten hpSC lines that are shared with collaborators and used for research purposes. Although these ten stem cell lines conform to all relevant US standards, they were derived outside the United States. New cell lines created under this study will be ISCO's first hpSC to be produced in the United States. ISCO's scientists, leaders the field of creating therapeutic cells from hpSC, will work with these lines targeting new treatments for human diseases. The company will also share these cells with other scientists to further clinical research. ISCO intends to derive and store these cells at its Oceanside facilities, which are designed to create cells suitable for clinical use.

Simon Craw, PhD, says, "These approvals, combined with our technology, make the establishment of a bank of immune matched stem cells practical and allow for the possibility of cell-based therapy to be economic for millions of people. We believe we are one of the first commercial entities in the United States to have progressed to this point."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and therapeutic applications, the potential benefits of collaborations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and therapies, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
Or
Simon Craw, PhD, Vice President
760-940-6383
sc@intlstemcell.com

OCEANSIDE, Calif. -- (March 10, 2011) -- International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that its Executive Chairman, Kenneth C. Aldrich, will present at the ROTH 23rd Annual Orange County Growth Stock Conference at the Ritz Carlton Laguna Niguel in Dana Point, CA. on Wednesday, March 16, 2011 at 10:30 AM PDT (1:30PM EDT). The webcast can be viewed live at: http://www.wsw.com/webcast/roth24/isco/. The presentation will be archived and viewable at the same link for 90 days. After the Roth Conference, a link to the presentation will also be posted to the ISCO website, http://www.internationalstemcell.com.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed cell based skin care products through its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

CONTACTS

International Stem Cell Corporation

Kenneth C. Aldrich, Executive Chairman

1-760-940-6383

kaldrich@intlstemcell.com

OCEANSIDE, Calif. -- (March 10, 2011) -- International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that its Executive Chairman, Kenneth C. Aldrich, will present at the ROTH 23rd Annual Orange County Growth Stock Conference at the Ritz Carlton Laguna Niguel in Dana Point, CA. on Wednesday, March 16, 2011 at 10:30 AM PDT (1:30PM EDT). The webcast can be viewed live at: http://www.wsw.com/webcast/roth24/isco/. The presentation will be archived and viewable at the same link for 90 days. After the Roth Conference, a link to the presentation will also be posted to the ISCO website, http://www.internationalstemcell.com.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed cell based skin care products through its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

CONTACTS

International Stem Cell Corporation

Kenneth C. Aldrich, Executive Chairman

1-760-940-6383

kaldrich@intlstemcell.com

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today the achievement of a major milestone in its efforts to establish a bank of immune-matched parthenogenetic stem cells in the United States by receiving the statutory approvals required to move forward with the next phase of its stem cell banking program.

An independent Stem Cell Research Oversight (SCRO) committee approved ISCO's program to obtain human oocytes (eggs) in California. The independent SCRO committee is responsible for reviewing the scientific rationale, ethics and compliance with State and Federal regulations and guidelines for studies involving human stem cells. This approval in combination with the earlier reported Institutional Review Board (IRB) clearance with regard to medical safety opens the way for ISCO's stem cell banking program to begin registering clinical investigators. ISCO's study is designed to produce new clinical-grade human parthenogenetic stem cell lines that can be immune matched to millions of individuals for use in the emerging field of regenerative medicine.

ISCO's breakthrough discoveries have resulted in unique stem cells carrying distinct advantages over other human pluripotent stem cells. ISCO uses unfertilized oocytes to create human "parthenogenetic" stem cells (hpSCs). Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals.

Currently ISCO has a collection of ten hpSC lines that are shared with collaborators and used for research purposes. Although these ten stem cell lines conform to all relevant US standards, they were derived outside the United States. New cell lines created under this study will be ISCO's first hpSC to be produced in the United States. ISCO's scientists, leaders the field of creating therapeutic cells from hpSC, will work with these lines targeting new treatments for human diseases. The company will also share these cells with other scientists to further clinical research. ISCO intends to derive and store these cells at its Oceanside facilities, which are designed to create cells suitable for clinical use.

Simon Craw, PhD, says, "These approvals, combined with our technology, make the establishment of a bank of immune matched stem cells practical and allow for the possibility of cell-based therapy to be economic for millions of people. We believe we are one of the first commercial entities in the United States to have progressed to this point."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and therapeutic applications, the potential benefits of collaborations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and therapies, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
Or
Simon Craw, PhD, Vice President
760-940-6383
sc@intlstemcell.com